Exclusive Summary

• - Off‑patent molecule with US registration enables fast market entry via reliance pathways and hospital tenders across multiple countries.
• - Covers high‑burden infections (CAP, rickettsial diseases, chlamydia) with an IV option for inpatient and NPO patients needing immediate therapy.
• - Dual 100 mg/200 mg strengths support loading and maintenance dosing, cutting reconstitution steps and pharmacy/nursing workload.
• - Generic IV doxycycline typically delivers 30–70% cost savings versus originator or limited suppliers, fitting public tenders and private chains.
• - FDA‑level sterile quality and dossiers de‑risk procurement and accelerate registrations in many markets.